TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Present at the Cowen & Company 37th Annual Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 37th Annual Healthcare Conference in Boston, MA.

When:

  Wednesday, March 8, 2017 at 9:20 AM ET
 

Who:

Marcelo Bigal, M.D. Ph.D., SVP, Head of Global Specialty Development,
Mike Derkacz, SVP, Head of Global CNS,
Teva Pharmaceutical Industries Ltd.
 

Where:

http://wsw.com/webcast/cowen38/teva

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s Website at http://ir.tevapharm.com.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

EN
06/03/2017

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

Teva and Royalty Pharma Enter Agreement to Accelerate Development of P...

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- ...

 PRESS RELEASE

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at . An archived version of the webcast will be available within 24 hours after the...

Si Yong Ng
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

Felix Fischer ... (+7)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Oriflame, Samvardhana Motherson, Telecom Italia, International Personal Finance, Novelis, Intrum, Nexans, Italmatch Chemicals, Asmodee, Lecta, Hapag-Lloyd, Ontex, Modulaire, Vedanta Resources, Softbank Group, Teva

 PRESS RELEASE

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Piv...

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB, with a stable outlook TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch